ICU · SeaStar Medical Holding Corporation

SeaStar Medical operates in the acute care medtech space with its patented Selective Cytopheretic Device platform targeting hyperinflammation in organ failure patients. The FDA-approved pediatric QUELIMMUNE positions it as first-mover in a niche with no direct competitors for septic AKI in children on CRRT, while adult pivotal trials (NEUTRALIZE-AKI) and feasibility studies in cardiorenal syndrome could expand addressable market across AKI, ESRD, and inflammatory conditions. Six FDA Breakthrough designations signal regulatory priority and faster paths to approval, enhancing moat through organ-agnostic applicability integrated into existing CRRT/dialysis systems. This S-1/A registers resale of 1,664,543 shares by Lincoln Park under a $15M equity line executed April 25, 2025, following issuance of 23,641 commitment shares. Pricing at 97% of the lower of same-day low or 10-day average of three lowest closes ensures deep discount purchases (Regular up to $50K-$500K limits, accelerated up to 30% volume), with $342K already received from 138K shares sold. Full utilization requires additional registrations if exceeding registered shares, amplifying dilution risk—29.4% at April 20, 2026 base of 3.997M shares outstanding (post 1:10 reverse split Jan 2026). No direct proceeds from resale but up to $14.7M gross for working capital amid ongoing losses and capital needs; prior ATM raised $5.9M in 2025 from 0.9M shares. Balance sheet shows $10.4M net tangible book value ($2.71/share) at Dec 31, 2025 on 3.88M shares, diluting $1.34/share for new investors at $4.63 closing price. Litigation risks resolved favorably—class action dismissed with prejudice April 2026 over 2024 restatements alleging misstatements—but underscores accounting control issues. Management led by CEO Eric Schlorff (ex-Dow finance/ops) and new CFO Michael Messinger (biotech financings); independent board majority with healthcare expertise. Governance includes classified board, no cumulative voting, and anti-takeover provisions. Key risks center on dilution from variable-price sales, funding shortfalls if stock < $1 floor or ownership caps bind (4.99%/9.99%), and execution on adult trials amid cash burn. Equity line provides flexible non-dilutive bridge versus debt but exposes to overhang from resale pressure; prior shareholder suits highlight governance scrutiny. Overall, positions SeaStar for clinical milestones but demands vigilant dilution management in volatile microcap biotech trading.